🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the battle against superbug strains of the infection, according to scientists.

A Global Challenge

Gonorrhoea infections are on the rise globally, with figures suggesting more than 82 million instances annually. Especially elevated rates are observed in the African continent and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune step in the reality of rising global incidence, escalating drug resistance and the highly restricted therapeutic options currently available.”

Public health authorities are increasingly worried about the surge in antibiotic-resistant strains. The WHO has listed it as a "critical concern". A tracking program showed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Secure Authorization

One new antibiotic, alternatively called Nuzolvence, was authorized by the US FDA in recent days for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers anticipate that focused deployment of this new drug will help delay the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, gained clearance in the same week. This treatment, which is additionally indicated for UTIs, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to see it through.

“This milestone marks a significant shift in the therapy of superbug gonorrhoea, which up to this point has been outpacing medical innovation.”

Testing Data and Global Access

As per data released by a prominent scientific publication, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This establishes an equal footing with the existing first-line therapy, which combines a dual-drug approach. The study involved over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the ability to license and sell the drug in numerous regions with limited resources.

Medical professionals treating patients have shared positive views. The availability of a single-dose, oral treatment of this kind is described as a "critical tool" for gonorrhoea control. This is deemed crucial to lessen the impact of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea around the world.